103 related articles for article (PubMed ID: 1665840)
1. Antibody response to three doses of standard and double dose of trivalent oral polio vaccine.
Agarwal A; Sharma D; Kumari S; Khare S
Indian Pediatr; 1991 Oct; 28(10):1141-5. PubMed ID: 1665840
[TBL] [Abstract][Full Text] [Related]
2. Randomized, controlled trial of trivalent oral poliovirus vaccine (Sabin) starting at birth in Ghana.
Osei-Kwasi M; Afari EA; Mimura K; Obeng-Ansah I; Ampofo WK; Nkrumah FK
Bull World Health Organ; 1995; 73(1):41-6. PubMed ID: 7704924
[TBL] [Abstract][Full Text] [Related]
3. Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies.
Mas Lago P; Ramon Bravo J; Andrus JK; Comellas MM; Galindo MA; de Quadros CA; Bell E
Bull World Health Organ; 1994; 72(2):221-5. PubMed ID: 8205641
[TBL] [Abstract][Full Text] [Related]
4. Early immunization of neonates with trivalent oral poliovirus vaccine.
Weckx LY; Schmidt BJ; Herrmann AA; Miyasaki CH; Novo NF
Bull World Health Organ; 1992; 70(1):85-91. PubMed ID: 1314711
[TBL] [Abstract][Full Text] [Related]
5. [A study on immunization of polio vaccine. I. Observation on an improved immunization schedule].
Su W
Zhonghua Liu Xing Bing Xue Za Zhi; 1991 Oct; 12(5):281-3. PubMed ID: 1664295
[TBL] [Abstract][Full Text] [Related]
6. Effect of breast-feeding on seroresponse of infants to oral poliovirus vaccination.
John TJ; Devarajan LV; Luther L; Vijayarathnam P
Pediatrics; 1976 Jan; 57(1):47-53. PubMed ID: 174056
[TBL] [Abstract][Full Text] [Related]
7. [Thermostability and immunogenicity of trivalent oral poliovirus vaccine produced by different countries].
Kong J
Zhonghua Liu Xing Bing Xue Za Zhi; 1993 Jun; 14(3):151-4. PubMed ID: 8221837
[TBL] [Abstract][Full Text] [Related]
8. A cross-sectional sero epidemiological prevalence of polio virus antibodies post-immunization with three doses of TOPV.
Tswana SA; Berejena C; Moyo SR; Mudyarabikwa O
Cent Afr J Med; 1994 Nov; 40(11):303-5. PubMed ID: 7859270
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of three doses of oral polio immunization beginning within the first four days of life.
Bhatawdekar AM; Kumta NB; Dave KH; Bharucha BA
Indian Pediatr; 1990 Sep; 27(9):911-4. PubMed ID: 2286433
[TBL] [Abstract][Full Text] [Related]
10. Oral iodine supplementation does not reduce neutralizing antibody responses to oral poliovirus vaccine.
Taffs RE; Enterline JC; Rusmil K; Muhilal ; Suwardi SS; Rustama D; Djatnika ; Cobra C; Semba RD; Cohen N; Asher DM
Bull World Health Organ; 1999; 77(6):484-91. PubMed ID: 10427933
[TBL] [Abstract][Full Text] [Related]
11. Decision analysis in planning for a polio outbreak in the United States.
Jenkins PC; Modlin JF
Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
[TBL] [Abstract][Full Text] [Related]
12. [A study on immunization of polio vaccine. II. Comparison of responses obtained by different forms of polio vaccine].
Su W
Zhonghua Liu Xing Bing Xue Za Zhi; 1991 Oct; 12(5):284-5. PubMed ID: 1664296
[TBL] [Abstract][Full Text] [Related]
13. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
14. [A comparison of the effectiveness of mass immunization campaign of trivalent oral poliovirus vaccine (TOPV) by epidemiological serosurvey. Shandong Collaborating Group for Poliomyelitis Control and Surveillance, Jinan, Shandong].
Xu A
Zhonghua Liu Xing Bing Xue Za Zhi; 1992 Oct; 13(5):261-4. PubMed ID: 1338626
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial.
Sutter RW; John TJ; Jain H; Agarkhedkar S; Ramanan PV; Verma H; Deshpande J; Singh AP; Sreevatsava M; Malankar P; Burton A; Chatterjee A; Jafari H; Aylward RB
Lancet; 2010 Nov; 376(9753):1682-8. PubMed ID: 20980048
[TBL] [Abstract][Full Text] [Related]
16. Monovalent type 1 oral poliovirus vaccine in newborns.
el-Sayed N; el-Gamal Y; Abbassy AA; Seoud I; Salama M; Kandeel A; Hossny E; Shawky A; Hussein HA; Pallansch MA; van der Avoort HG; Burton AH; Sreevatsava M; Malankar P; Wahdan MH; Sutter RW
N Engl J Med; 2008 Oct; 359(16):1655-65. PubMed ID: 18923170
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of enhanced potency inactivated polio vaccine.
Singh J; Ravi RN; Dutta AK; Kumari S; Khare S
Indian Pediatr; 1992 Nov; 29(11):1353-6. PubMed ID: 1338200
[TBL] [Abstract][Full Text] [Related]
18. Monovalent type 1 oral poliovirus vaccine among infants in India: report of two randomized double-blind controlled clinical trials.
John TJ; Jain H; Ravishankar K; Amaresh A; Verma H; Deshpande J; Pallansch MA; Singh AP; Sreevatsava M; Burton A; Malankar P; Chatterjee A; Sutter RW
Vaccine; 2011 Aug; 29(34):5793-801. PubMed ID: 21641951
[TBL] [Abstract][Full Text] [Related]
19. Antibody response of infants in tropics to five doses of oral polio vaccine.
Chopra K; Kundu S; Chowdhury DS
J Trop Pediatr; 1989 Feb; 35(1):19-23. PubMed ID: 2709485
[TBL] [Abstract][Full Text] [Related]
20. Influence of host related factors on the antibody response to trivalent oral polio vaccine in Tunisian infants.
Triki H; Abdallah MV; Ben Aissa R; Bouratbine A; Ben Ali Kacem M; Bouraoui S; Koubaa C; Zouari S; Mohsni E; Crainic R; Dellagi K
Vaccine; 1997 Jul; 15(10):1123-9. PubMed ID: 9269056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
